MedPath

Comparative effect of second-generation antipsychotic blonanserin and aripiprazole on cognitive impairment in first-episode schizophrenia: An open-label trial

Not Applicable
Conditions
schizophrenia
Registration Number
JPRN-UMIN000010827
Lead Sponsor
Department of Neuropsychiatry St. Marianna University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

1) patients who had been treated with blonanserin or aripiprazole before study entry 2) comorbid central nervous system disorder 3) meeting DSM-IV-TR criteria for alcohol or other substance dependence 4) meeting DSM-IV-TR criteria for mental retardation 5) symptomatic or organic psychosis (including dementia) 6) taking tricyclic antidepressants 7) treatment with electroconvulsive therapy in the 12 weeks preceding the study 8) treatment with long-acting antipsychotics in the 12 weeks preceding the study 9) patients who are not voluntarily hospitalized 10) active expression of suicidal or homicidal ideation 11) pregnancy or breast feeding 12) inability to understand the study protocol

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Cognitive function: Brief Assessment of Cognition in Schizophrenia-Japanese version (BACS-J)
Secondary Outcome Measures
NameTimeMethod
Psychopathology: Positive And Negative Syndrome Scale (PANSS), Clinical Global Impression- Severity (CGI-S) Functional ability: Schizophrenia Cognitive Rating Scale- Japanese version (SCoRS-J), University of California, San Diego, Performance- Based Skills Assessment (UPSA) Subjective assessments: Schizophrenia Quality of Life Scale-Japanese version (SQLS-J), Subjective Well-being under Neuroleptic drug treatment Short form, Japanese version (SWNS-J) Adverse effects: Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS),Weight Laboratory tests
© Copyright 2025. All Rights Reserved by MedPath